RS51016B - Derivati indol-1-il sirćetne kiseline koji imaju aktivnost antagonista pgd2 - Google Patents
Derivati indol-1-il sirćetne kiseline koji imaju aktivnost antagonista pgd2Info
- Publication number
- RS51016B RS51016B RSP-2009/0534A RSP20090534A RS51016B RS 51016 B RS51016 B RS 51016B RS P20090534 A RSP20090534 A RS P20090534A RS 51016 B RS51016 B RS 51016B
- Authority
- RS
- Serbia
- Prior art keywords
- acetic acid
- antagonist activity
- alkyl
- pgd2
- pgd2 antagonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Jedinjenje formule (I):naznačeno time stoje R1 halo ili cijano; R2 je C1-C4 alkil; iR3 je fenil supstituisan sa jednim ili više supstituenata izabranih od C1-C6 alkil, halo ili -SO2(C1-C6 alkil);ili njegova farmaceutski prihvatljiva so, hidrat, rastvor ili kompleks. Prijava sadrži još 15 patentnih zahteva.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0505048.9A GB0505048D0 (en) | 2005-03-11 | 2005-03-11 | Compounds with PGD antagonist activity |
PCT/GB2006/000851 WO2006095183A1 (en) | 2005-03-11 | 2006-03-10 | 1-acetic acid-indole derivatives with pgd2 antagonist activity |
Publications (1)
Publication Number | Publication Date |
---|---|
RS51016B true RS51016B (sr) | 2010-10-31 |
Family
ID=34508918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2009/0534A RS51016B (sr) | 2005-03-11 | 2006-03-10 | Derivati indol-1-il sirćetne kiseline koji imaju aktivnost antagonista pgd2 |
Country Status (27)
Country | Link |
---|---|
US (1) | US8044088B2 (sr) |
EP (1) | EP1856045B1 (sr) |
JP (1) | JP2008532990A (sr) |
KR (1) | KR20070116633A (sr) |
CN (1) | CN101166721A (sr) |
AT (1) | ATE442356T1 (sr) |
AU (1) | AU2006221784A1 (sr) |
BR (1) | BRPI0608732A2 (sr) |
CA (1) | CA2601980A1 (sr) |
CY (1) | CY1109532T1 (sr) |
DE (1) | DE602006009080D1 (sr) |
DK (1) | DK1856045T3 (sr) |
ES (1) | ES2333161T3 (sr) |
GB (1) | GB0505048D0 (sr) |
HK (1) | HK1109628A1 (sr) |
HR (1) | HRP20090654T1 (sr) |
IL (1) | IL185844A0 (sr) |
MX (1) | MX2007011091A (sr) |
NO (1) | NO20074641L (sr) |
NZ (1) | NZ561747A (sr) |
PL (1) | PL1856045T3 (sr) |
PT (1) | PT1856045E (sr) |
RS (1) | RS51016B (sr) |
RU (1) | RU2007134456A (sr) |
SI (1) | SI1856045T1 (sr) |
WO (1) | WO2006095183A1 (sr) |
ZA (1) | ZA200708159B (sr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
PL2037967T3 (pl) | 2006-06-16 | 2017-07-31 | The Trustees Of The University Of Pennsylvania | Antagoniści receptora prostaglandyny D2 w leczeniu łysienia androgenowego |
JP5270542B2 (ja) | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
PL2051962T3 (pl) | 2006-08-07 | 2012-03-30 | Actelion Pharmaceuticals Ltd | Pochodne kwasu (3-amino-1,2,3,4-tetrahydro-9h-karbazol-9-ilo)-octowego |
GB0722216D0 (en) * | 2007-11-13 | 2007-12-27 | Oxagen Ltd | Use of crth2 antagonist compounds |
GB0722203D0 (en) * | 2007-11-13 | 2007-12-19 | Oxagen Ltd | Use of CRTH2 antagonist compounds |
DK2229358T3 (da) * | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
US7750027B2 (en) | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
CN101932571B (zh) * | 2008-01-18 | 2014-04-23 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
WO2009093029A1 (en) | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
US8470594B2 (en) * | 2008-04-15 | 2013-06-25 | President And Fellows Of Harvard College | Methods for identifying agents that affect the survival of motor neurons |
US9180114B2 (en) | 2008-11-26 | 2015-11-10 | President And Fellows Of Harvard College | Neurodegenerative diseases and methods of modeling |
EP2401269B1 (en) * | 2009-02-24 | 2014-01-29 | Merck Sharp & Dohme Corp. | Indole derivatives as crth2 receptor antagonists |
US8697869B2 (en) | 2010-03-22 | 2014-04-15 | Actelion Pharmaceuticals Ltd. | 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9H-carbazole derivatives and their use as prostaglandin D2 receptor modulators |
GB201103837D0 (en) | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
LT2697223T (lt) | 2011-04-14 | 2016-10-10 | Actelion Pharmaceuticals Ltd. | 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas |
DK2781508T3 (en) * | 2011-11-17 | 2019-03-11 | Kbp Biosciences Co Ltd | NITROGEN CONCENTRATED RING COMPOUNDS FOR USE AS CRTH2 ANTAGONISTS |
GB201121557D0 (en) | 2011-12-15 | 2012-01-25 | Oxagen Ltd | Process |
KR20140113667A (ko) | 2011-12-16 | 2014-09-24 | 아토픽스 테라퓨릭스 리미티드 | 호산구성 식도염의 치료를 위한 crth2 길항제 및 양성자 펌프 저해제의 조합 |
WO2014066568A1 (en) | 2012-10-24 | 2014-05-01 | Winthrop-University Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
KR102116978B1 (ko) | 2013-10-07 | 2020-05-29 | 삼성전자 주식회사 | 그래핀 소자 및 그 제조 방법 |
GB201322273D0 (en) | 2013-12-17 | 2014-01-29 | Atopix Therapeutics Ltd | Process |
PL3119779T3 (pl) | 2014-03-17 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2 |
GB201407820D0 (en) | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
GB201407807D0 (en) * | 2014-05-02 | 2014-06-18 | Atopix Therapeutics Ltd | Polymorphic form |
EP3256121B1 (en) | 2015-02-13 | 2024-08-07 | INSERM - Institut National de la Santé et de la Recherche Médicale | Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus |
US20200078351A1 (en) | 2015-07-30 | 2020-03-12 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
AU2016323262B2 (en) | 2015-09-15 | 2020-11-19 | Idorsia Pharmaceuticals Ltd | Crystalline forms |
KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
CN109180691B (zh) * | 2018-08-24 | 2020-07-10 | 武汉大学 | 一种c3-芳香型吡咯并吲哚类生物碱及其合成方法 |
EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
CN113425714B (zh) * | 2021-08-04 | 2022-04-26 | 华南师范大学 | 吲哚乙酸在制备防治慢性阻塞性肺病药物中的应用 |
CN114870018A (zh) * | 2022-05-12 | 2022-08-09 | 江南大学 | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5641800A (en) * | 1994-07-21 | 1997-06-24 | Eli Lilly And Company | 1H-indole-1-functional sPLA2 inhibitors |
KR100584650B1 (ko) * | 1998-03-31 | 2006-05-30 | 디 인스티튜트스 포 파마슈티컬 디스커버리, 엘엘씨 | 치환된 인돌알칸산 |
US7534897B2 (en) * | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
TW200307542A (en) * | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
SE0302232D0 (sv) * | 2003-08-18 | 2003-08-18 | Astrazeneca Ab | Novel Compounds |
GB0324763D0 (en) * | 2003-10-23 | 2003-11-26 | Oxagen Ltd | Use of compounds in therapy |
SE0303180D0 (sv) | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
GB0504150D0 (en) * | 2005-03-01 | 2005-04-06 | Oxagen Ltd | Microcrystalline material |
JP5270542B2 (ja) * | 2006-07-22 | 2013-08-21 | オキサジェン リミテッド | Crth2アンタゴニスト活性を有する化合物 |
DK2229358T3 (da) | 2007-12-14 | 2011-07-04 | Pulmagen Therapeutics Asthma Ltd | Indoler og deres terapeutiske anvendelse |
US7750027B2 (en) * | 2008-01-18 | 2010-07-06 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
WO2009093026A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
WO2009093029A1 (en) * | 2008-01-22 | 2009-07-30 | Oxagen Limited | Compounds having crth2 antagonist activity |
-
2005
- 2005-03-11 GB GBGB0505048.9A patent/GB0505048D0/en not_active Ceased
-
2006
- 2006-03-10 AU AU2006221784A patent/AU2006221784A1/en not_active Withdrawn
- 2006-03-10 US US11/908,401 patent/US8044088B2/en not_active Expired - Fee Related
- 2006-03-10 DE DE602006009080T patent/DE602006009080D1/de active Active
- 2006-03-10 DK DK06726357T patent/DK1856045T3/da active
- 2006-03-10 CN CNA2006800139287A patent/CN101166721A/zh active Pending
- 2006-03-10 MX MX2007011091A patent/MX2007011091A/es active IP Right Grant
- 2006-03-10 BR BRPI0608732A patent/BRPI0608732A2/pt not_active IP Right Cessation
- 2006-03-10 PT PT06726357T patent/PT1856045E/pt unknown
- 2006-03-10 KR KR1020077023379A patent/KR20070116633A/ko not_active Application Discontinuation
- 2006-03-10 CA CA002601980A patent/CA2601980A1/en not_active Abandoned
- 2006-03-10 NZ NZ561747A patent/NZ561747A/xx not_active IP Right Cessation
- 2006-03-10 WO PCT/GB2006/000851 patent/WO2006095183A1/en active Application Filing
- 2006-03-10 EP EP06726357A patent/EP1856045B1/en active Active
- 2006-03-10 ES ES06726357T patent/ES2333161T3/es active Active
- 2006-03-10 RS RSP-2009/0534A patent/RS51016B/sr unknown
- 2006-03-10 PL PL06726357T patent/PL1856045T3/pl unknown
- 2006-03-10 JP JP2008500270A patent/JP2008532990A/ja active Pending
- 2006-03-10 AT AT06726357T patent/ATE442356T1/de active
- 2006-03-10 SI SI200630491T patent/SI1856045T1/sl unknown
- 2006-03-10 RU RU2007134456/04A patent/RU2007134456A/ru not_active Application Discontinuation
-
2007
- 2007-09-10 IL IL185844A patent/IL185844A0/en unknown
- 2007-09-12 NO NO20074641A patent/NO20074641L/no not_active Application Discontinuation
- 2007-09-21 ZA ZA200708159A patent/ZA200708159B/xx unknown
-
2008
- 2008-04-08 HK HK08103897.0A patent/HK1109628A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 CY CY20091101280T patent/CY1109532T1/el unknown
- 2009-12-09 HR HR20090654T patent/HRP20090654T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20090654T1 (hr) | 2010-01-31 |
MX2007011091A (es) | 2007-11-22 |
DK1856045T3 (da) | 2010-01-04 |
SI1856045T1 (sl) | 2010-01-29 |
BRPI0608732A2 (pt) | 2016-11-08 |
EP1856045B1 (en) | 2009-09-09 |
EP1856045A1 (en) | 2007-11-21 |
PL1856045T3 (pl) | 2010-02-26 |
NO20074641L (no) | 2007-11-01 |
HK1109628A1 (en) | 2008-06-13 |
CY1109532T1 (el) | 2014-08-13 |
ES2333161T3 (es) | 2010-02-17 |
US8044088B2 (en) | 2011-10-25 |
ZA200708159B (en) | 2009-11-25 |
KR20070116633A (ko) | 2007-12-10 |
DE602006009080D1 (de) | 2009-10-22 |
US20100330077A1 (en) | 2010-12-30 |
ATE442356T1 (de) | 2009-09-15 |
CN101166721A (zh) | 2008-04-23 |
AU2006221784A1 (en) | 2006-09-14 |
IL185844A0 (en) | 2008-01-06 |
CA2601980A1 (en) | 2006-09-14 |
RU2007134456A (ru) | 2009-04-20 |
PT1856045E (pt) | 2009-12-09 |
WO2006095183A1 (en) | 2006-09-14 |
JP2008532990A (ja) | 2008-08-21 |
NZ561747A (en) | 2010-03-26 |
GB0505048D0 (en) | 2005-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS51016B (sr) | Derivati indol-1-il sirćetne kiseline koji imaju aktivnost antagonista pgd2 | |
NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
TW200740805A (en) | Novel compounds | |
GB0510584D0 (en) | Organic compounds | |
TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
CR8505A (es) | Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
NZ547615A (en) | Quinoline derivatives and use thereof as mycobacterial inhibitors | |
HRP20080052T3 (en) | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation | |
GEP20094605B (en) | Pyrazole derivatives, compositions containing such compounds and methods of use thereof | |
PE20060243A1 (es) | Derivados de 4-amino insustituido-5-(4-urea-fenil)-pirrolotriazina | |
TW200744587A (en) | Azaindole derivatives exhibiting PGD2 receptor antagonism | |
DK1755590T3 (da) | Kombination af glycopyrrolat og en beta2-adrenoceptoragonist | |
ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
TW200716650A (en) | Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-met autophosphorylation inhibiting potency | |
NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
EA200700103A1 (ru) | НОВЫЕ 2-ЗАМЕЩЁННЫЕ D-ГОМО-ЭСТРА-1,3,5(10)-ТРИЕНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 17β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ ТИПА 1 | |
WO2008114812A1 (ja) | Jak阻害剤 | |
AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
NO20071319L (no) | Fremgangsmate for fremstilling av isotiazolderivater. | |
WO2006029154A3 (en) | Novel compounds | |
NO20090332L (no) | 4-amino-3-arylamino-6-arylpyrazol[3,4-D]pyrimidinderivater, fremgangsmater for deres fremstilling og dere anvendelse som antivirale midler | |
WO2005053702A3 (en) | Anti-inflammatory agents | |
ATE465151T1 (de) | 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren | |
UA97957C2 (ru) | 2-{5-фтор-2-метил-3-[2-(фенилсульфонил)бензил]-1н-индол-1-ил}уксусная кислота и ее производные, их применение для лечения заболеваний, опосредствованных действием pgd2 на рецептор crth2 | |
WO2009019721A3 (en) | Quercetin derivatives as anti-cancer agents |